Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Camillo Porta

Showing results (241-250 of 388) with videos related to

Pageof 39
Sort By:
Kidney International|October 31, 2020
KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerCamillo Porta, Aristotelis Bamias, Farhad R Danesh, et al.
Journal of Bone Oncology|February 12, 2026
Psychosocial impact of COVID-19 pandemic on patients with solid malignancies and bone metastases (PsyCO-B): a multicentre prospective observational studyPaolo Taurisano, Ester Cornacchia, Maria Fara De Caro, et al.
Cancer Medicine|July 22, 2014
Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countriesCamillo Porta, Antonin Levy, Robert Hawkins, et al.
Kidney International|December 5, 2020
KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationJolanta Małyszko, Aristotelis Bamias, Farhad R Danesh, et al.
Journal of Translational Medicine|August 16, 2022
The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIsMarzia Del Re, Stefania Crucitta, Federico Paolieri, et al.
Hepatic Oncology|September 8, 2018
Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trialLorenza Rimassa, Camillo Porta, Ivan Borbath, et al.
Cancer Immunology, Immunotherapy : CII|December 14, 2020
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLCMarzia Del Re, Federico Cucchiara, Eleonora Rofi, et al.
European Journal of Cancer (Oxford, England : 1990)|July 3, 2022
Statin use improves the efficacy of nivolumab in patients with advanced renal cell carcinomaMatteo Santoni, Francesco Massari, Marc R Matrana, et al.
Cancer Treatment Reviews|June 22, 2011
Multidisciplinary management of metastatic renal cell carcinoma in the era of targeted therapiesBernard Escudier, Susanne Osanto, Börje Ljungberg, et al.
Clinical Genitourinary Cancer|March 20, 2022
Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World ComparisonMatteo Santoni, Gaetano Aurilio, Francesco Massari, et al.
Pageof 39

Showing results (241-250 of 388) with videos related to

Sort By:
Pageof 39
Kidney International|October 31, 2020
KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerCamillo Porta, Aristotelis Bamias, Farhad R Danesh, et al.
Journal of Bone Oncology|February 12, 2026
Psychosocial impact of COVID-19 pandemic on patients with solid malignancies and bone metastases (PsyCO-B): a multicentre prospective observational studyPaolo Taurisano, Ester Cornacchia, Maria Fara De Caro, et al.
Cancer Medicine|July 22, 2014
Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countriesCamillo Porta, Antonin Levy, Robert Hawkins, et al.
Kidney International|December 5, 2020
KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationJolanta Małyszko, Aristotelis Bamias, Farhad R Danesh, et al.
Journal of Translational Medicine|August 16, 2022
The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIsMarzia Del Re, Stefania Crucitta, Federico Paolieri, et al.
Hepatic Oncology|September 8, 2018
Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trialLorenza Rimassa, Camillo Porta, Ivan Borbath, et al.
Cancer Immunology, Immunotherapy : CII|December 14, 2020
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLCMarzia Del Re, Federico Cucchiara, Eleonora Rofi, et al.
European Journal of Cancer (Oxford, England : 1990)|July 3, 2022
Statin use improves the efficacy of nivolumab in patients with advanced renal cell carcinomaMatteo Santoni, Francesco Massari, Marc R Matrana, et al.
Cancer Treatment Reviews|June 22, 2011
Multidisciplinary management of metastatic renal cell carcinoma in the era of targeted therapiesBernard Escudier, Susanne Osanto, Börje Ljungberg, et al.
Clinical Genitourinary Cancer|March 20, 2022
Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World ComparisonMatteo Santoni, Gaetano Aurilio, Francesco Massari, et al.
Pageof 39